[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-350771-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-350771-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","il1rap-antibodydrug-conjugates-potently-target-primary-and-metastatic-diseases-in-multiple-oncofusion-driven-cancers","IL1RAP Antibody–Drug Conjugates Potently Target Primary and Metastatic Diseases in Multiple Oncofusion-Driven Cancers","","Gene fusions from chromosomal rearrangements act as oncogenic drivers in human cancers. The article reports that EWSR1–ETS oncofusions in Ewing sarcoma induce surface IL1 receptor accessory protein (IL1RAP), and engineered IL1RAP-targeting antibody–drug conjugates (ADCs) with distinct cytotoxic payloads block tumor growth, drive durable regressions in xenograft models, and reduce metastatic spread in vivo. IL1RAP is also induced by other oncofusions, creating broader vulnerability to IL1RAP ADC therapy.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/il1rap-antibodydrug-conjugates-potently-target-primary-and-metastatic-diseases-in-multiple-oncofusion-driven-cancers/350771/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/il1rap-antibodydrug-conjugates-potently-target-primary-and-metastatic-diseases-in-multiple-oncofusion-driven-cancers/350771.png","ImageObject",300,407,{"name":42,"@type":43},"anakgang17","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-18","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the key cancer target discussed in the article?","Question",{"text":63,"@type":64},"The article focuses on the IL1RAP surface protein, which is induced by multiple oncogenic fusions across different cancers.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were the IL1RAP antibody–drug conjugates (ADCs) designed to work?",{"text":68,"@type":64},"The ADCs use antibody binding to IL1RAP on tumor cells to deliver cytotoxic payloads, leading to targeted killing and, for cleavable linkers, potential bystander effects in the tumor microenvironment.",{"name":70,"@type":61,"acceptedAnswer":71},"What evidence supports effectiveness against both primary and metastatic disease?",{"text":72,"@type":64},"IL1RAP-targeting ADCs potently blocked primary tumor growth, produced durable regression in Ewing sarcoma xenografts, and diminished metastatic dissemination in vivo, with additional efficacy shown in other oncofusion-driven models.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},350771,1790268188,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},962090883568,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","RESEARCH ARTICLE  \nIL1RAP Antibody–Drug Conjugates Potently Target Primary and Metastatic Diseases in Multiple Oncofusion-Driven Cancers   \nHai-Feng Zhang1,2, Edouard De Dreuzy3, Yue Zhou Huang2, Seungmin Shin4, Qing-Feng Huang5,6,  \nAlberto Delaidelli2,7, Xiaqiu Yang2, Virginia Adamiak2, Andrew Lytle1,8, Aarzoo Arzoo2, Michael M. Lizardo2, Qiaochu Lin2, Shreya Sanadi2, Melanie Rouleau2, Lu-Xin Liu5,6, Li-Yan Xu5,6, En-Min Li5,9, Raymond Lai10, Clémentine Primus3, Soha Reda El Sayed3, Lucas Bourhis3, Delphine Genin3, Lucas Demontrond3,  \nLucie Bouquet3, Laura Labarthe Démolis3, Amandine Barberot3, Stephane Lameynardie3, Alexis Delabrière3, Haiqing Hua11, Junjie Yang11, Rieko Ishima12, Roland Imle13, Ana Banito13, Graham W. Slack8, Kerry J. Savage8, John M. Maris14, 15, Kristopher R. Bosse14, 15, Dimiter S. Dimitrov4, Christian Steidl1,8, Wei Li4,  \nRichard C.A. Sainson3, and Poul H. Sorensen1,2  \nGene fusions generated by chromosomal rearrangements function as oncogenic  \ndrivers in human cancers. We previously showed that EWSR1–ETS oncofusions of Ewing sarcoma directly induce surface expression of IL1 receptor accessory protein (IL1RAP), which along with limited expression in healthy tissues except in the placenta nominate IL1RAP as a promising Ewing sarcoma immunotherapy target. We therefore engineered antibody–drug conjugates (ADC) with different cytotoxic payloads to target IL1RAP. ADCs potently blocked tumor growth and induced durable regression of Ewing sarcoma xenografts in mice and diminished metastatic dissemination in vivo. Moreover, we show that other oncofusions also induce IL1RAP expression in diverse cancers, including NPM–ALK in anaplastic large cell lymphoma and ETV6–NTRK3 in multiple tumor types. IL1RAP expression rendered these malignancies similarly vulnerable to IL1RAP-targeting ADCs, which effectively blocked the growth of ALCL xenografts and syngeneic ETV6−NTRK3+ sarcomas. Lack of detectable normal tissue toxicity, including in nonhuman primates, supports the further clinical translation of IL1RAP-targeting ADCs.  \nSIGNIFICANCE: The IL1RAP surface protein is induced by multiple oncogenic fusions, including EWSR1–ETS, NPM–ALK, and EN in distinct malignancies, rendering these cancers vulnerable to anti-IL1RAP ADCs. We demonstrate that IL1RAP-targeting ADCs have potent efficacy in both primary and metastatic diseases and are well tolerated in nonhuman primates, warranting their further clinical translation.  \nINTRODUCTION  \nImmunotherapy strategies such as chimeric antigen receptor (CAR) T-cell therapy and immune checkpoint inhibitors targeting PD-1, PD-L1, and CTLA-4 have revolutionized clinical oncology over the last decade or so (1–3) . However, these approaches remain challenging for many solid malignancies, given the presence of a metabolically harsh and immunosuppressive tumor microenvironment (TME) and reduced immune cell infiltration, particularly in genomically quiet pediatric solid cancers (3–5) . Antibody–drug conjugates (ADC) are a class of targeted therapy modality in cancer that preferentially deliver conjugated cytotoxic payloads to tumors by harnessing the specificity of antibody binding to specific antigens on the tumor cell surface (6–8) . Since 2010, ADCs represent one of the most rapidly expanding treatment  \n1Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada. 2Department of Molecular Oncology, BC Cancer Agency, Vancouver, Canada. 3Advesya Therapeutics, Paris, France. 4Center for Antibody Therapeutics, Division of Infectious Diseases, Department of Medicine, University of Pittsburgh Medical School, Pittsburgh, Pennsylvania. 5Department of Pathology, Second Affiliated Hospital, Shantou University Medical College, Shantou, China. 6 Institute of Oncologic Pathology, Shantou University Medical College, Shantou, China. 7Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts. 8Centre for Lymphoid Canc","cbCaivOhZhmFjObO","https://ap.wps.com/l/cbCaivOhZhmFjObO","pdf",12382698,25,"English","# Abstract\n# Significance\n# Introduction","[{\"question\":\"What is the key cancer target discussed in the article?\",\"answer\":\"The article focuses on the IL1RAP surface protein, which is induced by multiple oncogenic fusions across different cancers.\"},{\"question\":\"How were the IL1RAP antibody–drug conjugates (ADCs) designed to work?\",\"answer\":\"The ADCs use antibody binding to IL1RAP on tumor cells to deliver cytotoxic payloads, leading to targeted killing and, for cleavable linkers, potential bystander effects in the tumor microenvironment.\"},{\"question\":\"What evidence supports effectiveness against both primary and metastatic disease?\",\"answer\":\"IL1RAP-targeting ADCs potently blocked primary tumor growth, produced durable regression in Ewing sarcoma xenografts, and diminished metastatic dissemination in vivo, with additional efficacy shown in other oncofusion-driven models.\"}]","IL1RAP Antibody–Drug Conjugates Potently Target Primary and Metastatic Diseases in Multiple Oncofusion-Driven Cancers | PDF",1790091004,63,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/04d55e912b8bac10b7bd47d71d1da70b.webp",983,1315,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/00761008f35bd0dd59d774c58bfdd83e.webp",982,1314,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1148d02be8af3d9305f3892b610193c7.webp",981,1312,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/64c6dec7f4566975c41daa8892849510.webp",980,1311]